Université de Paris, Faculté de Médecine, 75006 Paris, France; Department of Radiology, Assistance Publique-Hôpitaux des Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, 75015 Paris, France; Institut National de la Santé et de la Recherche Médicale, PARCC, UMR970, 75015 Paris, France.
Université de Paris, Faculté de Médecine, 75006 Paris, France; Institut National de la Santé et de la Recherche Médicale, PARCC, UMR970, 75015 Paris, France; CIC1418 and DMU CARTE, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, 75015 Paris, France.
Diagn Interv Imaging. 2021 Dec;102(12):717-725. doi: 10.1016/j.diii.2021.06.007. Epub 2021 Jul 13.
The purpose of this study was to evaluate the association between coronary artery calcium (CAC) visual score and 6-month mortality in patients with coronavirus disease 2019 (COVID-19).
A single-center prospective observational cohort was conducted in 169 COVID-19 consecutive hospitalized patients between March 13 and April 1, 2020, and follow-up for 6-months. A four-level visual CAC scoring was assessed by analyzing images obtained after the first routine non-ECG-gated CT performed to detect COVID-19 pneumonia.
Among 169 confirmed COVID-19 patients (118 men, 51 women; mean age, 65.6 ± 18.8 [SD] years; age range: 30-95 years) 63 (37%) presented with either moderate (n = 26, 15.3%) or heavy (n = 37, 21.8%) CAC detected by CT and 20 (11.8%) had history of cardiovascular disease requiring specific preventive treatment. At six months, mortality rate (45/169; 26.6%) increased with magnitude of CAC and was 7/64 (10.9%), 11/42 (26.2%), 10/26 (38.5%), 17/37 (45.9%) for no-CAC, mild-CAC, moderate-CAC and heavy-CAC groups, respectively (P = 0.001). Compared to the no CAC group, risk of death increased after adjustment with magnitude of CAC (HR: 2.23, 95% CI: 0.73-6.87, P = 0.16; HR: 2.78, 95% CI: 0.85-9.07, P0.09; HR: 5.38, 95% CI: 1.57-18.40, P = 0.007; in mild CAC, moderate and heavy CAC groups, respectively). In patients without previous coronary artery disease (154/169; 91%), mortality increased from 10.9% to 45.8% (P = 0.001) according to the magnitude of CAC categories. After adjustment, presence of moderate or heavy CAC was associated with higher mortality (HR: 2.26, 95% CI: 1.09-4.69, P = 0.03).
By using non-ECG-gated CT during the initial pulmonary assessment of COVID-19, heavy CAC is independently associated with 6-month mortality in patients hospitalized for severe COVID-19 pneumonia.
本研究旨在评估 2019 年冠状病毒病(COVID-19)患者冠状动脉钙(CAC)视觉评分与 6 个月死亡率之间的关系。
2020 年 3 月 13 日至 4 月 1 日期间,对 169 例连续住院的 COVID-19 患者进行了单中心前瞻性观察队列研究,并进行了 6 个月的随访。通过分析首次常规非心电图门控 CT 检查获得的图像来评估 CAC 的四级视觉评分,以检测 COVID-19 肺炎。
在 169 例确诊的 COVID-19 患者中(118 名男性,51 名女性;平均年龄 65.6±18.8[SD]岁;年龄范围:30-95 岁),63 例(37%)患者通过 CT 检测到中度(n=26,15.3%)或重度(n=37,21.8%)CAC,20 例(11.8%)患者有需要特定预防治疗的心血管疾病史。6 个月时,死亡率(45/169;26.6%)随 CAC 程度增加而升高,分别为无 CAC、轻度 CAC、中度 CAC 和重度 CAC 组的 7/64(10.9%)、11/42(26.2%)、10/26(38.5%)和 17/37(45.9%)(P=0.001)。与无 CAC 组相比,在校正 CAC 程度后,死亡风险增加(HR:2.23,95%CI:0.73-6.87,P=0.16;HR:2.78,95%CI:0.85-9.07,P=0.09;HR:5.38,95%CI:1.57-18.40,P=0.007;在轻度 CAC、中度和重度 CAC 组中)。在无既往冠状动脉疾病的患者(154/169;91%)中,死亡率根据 CAC 分类的严重程度从 10.9%增加到 45.8%(P=0.001)。在校正后,中度或重度 CAC 与更高的死亡率相关(HR:2.26,95%CI:1.09-4.69,P=0.03)。
通过在 COVID-19 肺部初始评估期间使用非心电图门控 CT,重度 CAC 与因严重 COVID-19 肺炎住院的患者 6 个月死亡率独立相关。